Bicara Therapeutics

Public

Cambridge, MassachusettsConsumer Products and Services (B2C)https://www.bicara.com

Last Round

IPO Announced

Sep 16, 2024

Est. Valuation

$881.4M

Total Funding Raised

$675M

Company Overview

Bicara Therapeutics, Inc. is a publicly traded, clinical-stage biopharmaceutical company that develops bifunctional therapies for solid tumors. Founded in 2018, the company's approach is to engineer biologics that combine the precision of tumor-targeting antibodies with the power of tumor microenvironment modulators. Its lead program, ficerafusp alfa (BCA101), is a first-in-class bifunctional antibody that targets both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β). Ficerafusp alfa is in clinical development for several cancer types, with a primary focus on head and neck squamous cell carcinoma (HNSCC). The company is headquartered in Boston, Massachusetts, and trades on the Nasdaq under the symbol BCAX.

Sector

Consumer Products and Services (B2C)

AI Layer

Non-AI

Keywords

first-in-class bifunctional antibodyEGFR and TGF-β dual-targeting antibodydual-action antibody platformhead and neck squamous cell carcinoma (HNSCC) therapysolid tumor therapeuticstumor microenvironment immunomodulationTGF-β trapEGFR-expressing solid tumor therapycutaneous squamous cell carcinoma (cSCC) therapysquamous non-small cell lung cancer (SqNSCLC) therapyclinical-stage oncology drug development

Bicara Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Bicara Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Bicara Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO Announced	Sep 16, 2024
Series C	Dec 12, 2023
Series B	Mar 6, 2023
Seed	Mar 15, 2021

View all Funding Rounds

Bicara Therapeutics Investors

Notable investors and investment history

Bicara Therapeutics investors
Investor	Rounds
Deerfield Management	Series C
Janus Henderson Group	Series B, Series C
RA Capital Management	IPO, Series C, Series B
Omega Funds	Series B, Series C
Fairmont Capital	Series C
Braidwell	Series C
Heartland Healthcare Capital	Series B

View all Investors

Bicara Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Bicara Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range99

Year Founded2018

Last FundingSep 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.